https://mb.cision.com/Public/18595/3730027/a7faa49f29ec633e_800x800ar.png
** UCB=E2=80=99s Board of Directors appoints Jonathan Peacock as new Chair
------------------------------------------------------------
Brussels (Belgium), 9 March 2023 =E2=80=93 7.00 am CET (CET) =E2=80=93 UCB =
SA/NV announces the following changes to its Board of Directors.
During its meeting on March 8, 2023 UCB=E2=80=99s Board of Directors electe=
d Jonathan Peacock, currently Independent Director and Chair of the Audit C=
ommittee at UCB, as Chair of UCB's Board of Directors with effect as of Mar=
ch 9, 2023. Fiona du Monceau, currently ad interim Chair of the Board, will=
revert to her role as Vice Chair of the Board. Ad interim, Jonathan Peacoc=
k will also keep his role as Chair of the Audit Committee at UCB.=C2=A0
Jean-Christophe Tellier, UCB's CEO said: =E2=80=9CJonathan Peacock is a hig=
hly respected and appreciated member of the Board and Chair of its Audit Co=
mmittee since 2021, bringing a wealth of expertise and strategic leadership=
. We are delighted to see Jonathan, who always puts the patient=E2=80=99s p=
erspective first, take on the role as Chair of the Board of UCB. Special th=
ank you to Fiona du Monceau who acted as ad interim Chair during year-end c=
losing on top of her duties.=E2=80=9D
=E2=80=9CI am thrilled to take on this unique opportunity and continue to w=
ork with such inspiring and talented people across the Board and UCB. The p=
ast years as Chair of the Audit Committee have provided me in-depth knowled=
ge of the company, its culture and strategy. I look forward to now also bri=
nging my expertise and leadership to the role of Chairman of UCB and accomp=
anying UCB on the exciting journey it has ahead, striving to help people to=
live the best life they can.=E2=80=9D =C2=A0said Jonathan Peacock.
Jonathan Peacock joined the Board of UCB in 2021 as an Independent Director=
and Chair of the Audit Committee. He currently serves as Chair of the Boar=
d of Avantor Inc =C2=A0and is a member of the Nominating and Governance Com=
mittee. He also serves on the Board of 2 private companies, Bluesphere Bio,=
as Chairman, and Real Chemistry.=C2=A0
From 2014 to May 2021, Mr. Peacock served as the Chairman of Bellerophon Th=
erapeutics, Inc. a clinical stage biotherapeutics company, and was its CEO =
from 2014 to 2016. He also served as Chairman of Arix Bioscience plc from 2=
016-2020 and as Chair of the Audit and Finance Committee of Kite Pharma fro=
m 2014-17 and Member of the Board of Genmab A/S until November 2021. Mr. Pe=
acock held Global CFO roles at Amgen and Novartis Pharma and leadership rol=
es in Strategy and Corporate Finance as a partner at McKinsey and Price Wat=
erhouse. He has experience in emerging Biotechnology, big Pharma and Corpor=
ate Finance in Europe, the US and Asia. He also has extensive IPO and fund-=
raising experience on NASDAQ, NYSE and LSE.=C2=A0
More detailed bios of Jonathan Peacock and Fiona du Monceau are available o=
n ucb.com: UCB Governance | UCB (https://www.ucb.com/investors/UCB-Governan=
ce) .=C2=A0
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte
T +32.2.559.94.14=C2=A0
email antje.witte@ucb.com=C2=A0
Corporate Communications
Laurent Schots=C2=A0
T +32.2.559.92.64=C2=A0
email laurent.schots@ucb.com
About UCB=C2=A0
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8,700 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
Forward looking statements=C2=A0
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: the gl=
obal spread and impact of COVID-19, changes in general economic, business a=
nd competitive conditions, the inability to obtain necessary regulatory app=
rovals or to obtain them on acceptable terms or within expected timing, cos=
ts associated with research and development, changes in the prospects for p=
roducts in the pipeline or under development by UCB, effects of future judi=
cial decisions or governmental investigations, safety, quality, data integr=
ity or manufacturing issues; potential or actual data security and data pri=
vacy breaches, or disruptions of our information technology systems, produc=
t liability claims, challenges to patent protection for products or product=
candidates, competition from other products including biosimilars, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws, and hiring and retention=
of its employees. There is no guarantee that new product candidates will b=
e discovered or identified in the pipeline, will progress to product approv=
al or that new indications for existing products will be developed and appr=
oved. Movement from concept to commercial product is uncertain; preclinical=
results do not guarantee safety and efficacy of product candidates in huma=
ns. So far, the complexity of the human body cannot be reproduced in comput=
er models, cell culture systems or animal models. The length of the timing =
to complete clinical trials and to get regulatory approval for product mark=
eting has varied in the past and UCB expects similar unpredictability going=
forward. Products or potential products, which are the subject of partners=
hips, joint ventures or licensing collaborations may be subject to differen=
ces disputes between the partners or may prove to be not as safe, effective=
or commercially successful as UCB may have believed at the start of such p=
artnership. UCB=E2=80=99s efforts to acquire other products or companies an=
d to integrate the operations of such acquired companies may not be as succ=
essful as UCB may have believed at the moment of acquisition. Also, UCB or =
others could discover safety, side effects or manufacturing problems with i=
ts products and/or devices after they are marketed. The discovery of signif=
icant problems with a product similar to one of UCB=E2=80=99s products that=
implicate an entire class of products may have a material adverse effect o=
n sales of the entire class of affected products. Moreover, sales may be im=
pacted by international and domestic trends toward managed care and health =
care cost containment, including pricing pressure, political and public scr=
utiny, customer and prescriber patterns or practices, and the reimbursement=
policies imposed by third-party payers as well as legislation affecting bi=
opharmaceutical pricing and reimbursement activities and outcomes. Finally,=
a breakdown, cyberattack or information security breach could compromise t=
he confidentiality, integrity and availability of UCB=E2=80=99s data and sy=
stems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and it does not reflect any potenti=
al impact from the evolving COVID-19 pandemic, unless indicated otherwise. =
UCB is following the worldwide developments diligently to assess the financ=
ial significance of this pandemic to UCB. UCB expressly disclaims any duty =
to update any information contained in this press release, either to confir=
m the actual results or to report or reflect any change in its forward-look=
ing statements with regard thereto or any change in events, conditions or c=
ircumstances on which any such statement is based, unless such statement is=
required pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.=C2=A0
GenericFile
UCB PR Board Chairman March 9 2023 ENG (https://mb.cision.com/Public/18595/=
3730027/a7e97eeb89550851.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x130792x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01